The New Scientist piece correctly flags a critical oversight in long COVID management: many exercise-based interventions have been promoted without adequately addressing post-exertional malaise (PEM), the debilitating worsening of symptoms following minimal physical or cognitive effort. However, the coverage stops short of connecting this to decades of similar missteps in ME/CFS care, the flawed methodologies behind influential trials, and the broader pattern of dismissing patient reports in post-viral illnesses affecting an estimated 65 million people worldwide.

A landmark example is the 2011 PACE trial (peer-reviewed, The Lancet, n=641 ME/CFS patients, randomized controlled design comparing graded exercise therapy (GET), cognitive behavioral therapy, and standard medical care). It concluded GET was moderately effective, yet independent re-analyses (e.g., 2018 BMC Psychology paper by Wilshire et al.) exposed major limitations: outcome measures were altered after trial commencement, objective actigraphy data were downplayed, and participants were not stratified for PEM severity. Long-term follow-up showed no sustained benefit and reports of harm, leading UK NICE guidelines to withdraw GET recommendations in 2021.

Recent long COVID research reinforces the pattern. A 2023 Nature Reviews Microbiology article by Davis, McCorkell, and colleagues (narrative synthesis drawing on dozens of studies, including cohort research with thousands of participants) highlights PEM in up to 70% of long COVID cases, linking it to measurable physiological disruptions like mitochondrial dysfunction, endothelial damage, and immune dysregulation rather than deconditioning. A separate 2022 longitudinal cohort study in Nature Communications (approx. 500 patients, repeated symptom tracking and physiological testing over months) found that those following generic exercise advice experienced higher rates of relapse, with limitations including self-selection bias but strengths in objective biomarker correlations. These contrast with smaller, short-term trials (often n<100, lacking PEM screening) that underpinned early 'exercise as medicine' guidance from bodies like WHO in 2021.

What much original coverage missed is the patient-led evidence base and historical parallels. Surveys by organizations such as Long COVID Physio (over 3,000 international respondents, cross-sectional anonymous questionnaire) report that 80% experienced harm from graded activity, mirroring ME/CFS cohorts. This isn't isolated; post-viral syndromes after EBV, SARS-1, and even influenza have shown similar PEM patterns, frequently psychologized by clinicians. The orthodoxy that 'movement is always rehabilitative' fails when applied to bioenergetic limitations, risking prolonged disability instead of recovery.

Genuine analysis reveals a systemic lag: medicine has been slow to integrate lived experience with rigorous stratification in trials. The solution lies in 'pacing' protocols that respect energy envelopes, coupled with research that screens for PEM as a core variable. Until guidelines evolve, millions remain at risk of iatrogenic harm, exposing how post-viral crises are too often minimized.